Biosight is dedicated to providing hope and cure to cancer patients around the world.
We seek to develop advanced therapeutics to enable safer and more effective treatment for life-threatening diseases, to improve the outcome and quality of life for patients with cancer and related diseases.
for Oncology & Hematological Disorders
Biosight Receives Orphan Medicinal Product Designation from EMA for Aspacytarabine (BST-236) for AML Treatment
Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs